Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03053063 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

883

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG: SEL
DRUG: Placebo to match SEL 6 mg
DRUG: Placebo to match SEL 18 mg

Sponsor

Gilead Sciences